“Introducing ‘HEDGE’: Sequential Intravesical Gemcitabine-Based Thermochemotherapy (HIVEC) Plus Docetaxel As a Potential Novel Bladder-Sparing Strategy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer”. Archivio Italiano Di Urologia E Andrologia, vol. 98, no. 3, Sept. 2026, https://doi.org/10.4081/aiua.2026.15738.